Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age

Journal of Surgical Oncology

Volumn 103, Issue 1, 2011, Pages 25-33

  Onozato, Wataru ^a   Yamashita, Keishi ^a   Yamashita, Kazuya ^a   Kuba, Tatsuru ^b   Katoh, Hiroshi ^a   Nakamura, Takatoshi ^a   Sato, Takeo ^a   Ihara, Atsushi ^a   Okayasu, Isao ^a   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

colorectal cancer; k ras mutation; prognosis

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; VALIDATION PROCESS;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, RAS; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650635386     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21710     Document Type: Article

References (57)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
2. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
3. Denetru GD, von Mehren M, Blanke CD, et al.: Efficiency and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
4. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
5. Paez JG, Janne PS, Lee JC, et al.: EGFR mutations in lung cancer: Correlation with clinical response to gefinitib therapy. Science 2004; 304: 1497-1500.
6. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
7. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
8. Pterson MC, Dietrich KD, Danyluk J, et al.: Correlation between c-erb-B2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51: 556-567.
9. Taniguchi M, Nishida T, Hirota S, et al.: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-4300.
10. Singer S, Rubin BP, Lux ML, et al.: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-3905.
11. Schubbert S, Shannou K, G B,: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
12. Shirasawa S, Furuse M, Yokoyama N, et al.: Altered growth of human colon cancer cell lines disrupted at activated K-ras. Science 1993; 260: 85-88.
13. Okada F, Rak JW, Croix BS,: Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cell. Proc Natl Acad Sci USA 1998; 95: 3609-3614.
14. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 2: 532-535.
15. Benhattar J, Losi L, Chaubert P, et al.: Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993; 104: 1044-1048.
16. Tanaka M, Omura K, Watanabe Y, et al.: Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 1994; 57: 57-64.
17. Span M, Moerkerk PT, De Goeij AF, et al.: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 1996; 69: 241-245.
18. Cerottini JP, Caplin S, Saraga E, et al.: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998; 175: 198-202.
19. Pajkos G, Kiss I, Sandor J, et al.: The prognostic value of the presence of mutations at the codon 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 2000; 20: 1695-1701.
20. Andersen SN, Lovig T, Breivik J, et al.: K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 1997; 32: 62-69.
21. Hardingham JE, Butler WJ, Roder D, et al.: Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 1998; 42: 669-672.
22. Tortola S, Marcuello E, Gonzalez I, et al.: p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17: 1375-1381.
23. Bouzourence H, Gervaz P, Cerottini JP, et al.: p53 and K-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000; 36: 1008-1015.
24. Esteller M, Gonzalez S, Risques RA, et al.: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304.
25. Pan ZZ, Wan DS, Chen G, et al.: Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol 2004; 10: 3688-3690.
26. Hsieh JS, Lin SR, Chang MY, et al.: APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 2005; 71: 336-343.
27. Locker GY, Hammilton S, Harris J, et al.: ASCO 2006 update of recommendation for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
28. Allegra CJ, Jessup JM, Somerfield MR, et al.: American Society of Clinical Oncology provisional clinical opinion: Testing for K-RAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
29. Yamashita K, Tatebayashi T, Shinoda H,: Simplified rapid non-radioactive PCR-SSCP method applied to K-ras mutation analysis. Pathol Int 1996; 46: 801-804.
30. Yamashita K, Kuba T, Shinoda H, et al.: Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 1998; 109: 704-711.
31. Yamashita K, Kida Y, Shinoda H, et al.: K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination. Jpn J Cancer Res 1999; 90: 240-248.
32. Yamashita K, Yoshida T, Shinoda H,: Novel method for simultaneous analysis of p53 and k-ras mutations and p53 protein expression in single histologic sections. Arch Pathol Lab Med 2001; 125: 347-352.
33. Yasui W, Yokozaki H, Shimamoto F, et al.: Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. Pathol Int 1999; 49: 763-774.
34. Araujo SE, Bernardo WM, Habr-Gama A,: DNA ploidy status and prognosis in colorectal cancer: A meta-analysis of published data. Dis Colon Rectum 2007; 50: 1800-1810.
35. Zhou W, Goodman SN, Galizia G,: Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002; 359: 219-225.
36. Ribic CM, Sargent DJ, Moore MJ,: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy. N Engl J Med 2003; 349: 247-257.
37. Andre T, Boni C, Mounedji-Boudiaf L,: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
38. Kuebler JP, Wieand HS, O'Connell MJ,: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage 2 and 3 colon cancer: Results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
39. Andreyev HJ, Norman AR, Cunningham D,: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90: 675-684.
40. Andreyev HJNA, Cunningham D, Oates J, et al.: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL2' study. Br J Cancer 2001; 85: 692-696.
41. Goel A, Nagasaka T, Arnold CN, et al.: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 32: 127-138.
42. Young J, Simms LA, Biden KG, et al.: Features of colorectal canecrs with high-level microsatellite instability occurring in familial and sporadic settings: Parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107-2116.
43. Liu B, Farrington SM, Petersen GM, et al.: Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995; 1: 348-352.
44. Whitehall VL, Walsh MD, Young J, et al.: Methylation of O6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsattelite instability. Cancer Res 2001; 61: 827-830.
45. Halling KC, French AJ, McDonnell SK,: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancer. J Natl Cancer Inst 1999; 91: 1295-1303.
46. Lengauer C, Kinzler KW, B V,: Genetic instability in colorectal cancers. Nature 1997; 386: 623-627.
47. Samowitz WS, Sweeney C, Herrick J,: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancer. Cancer Res 2005; 65: 6063-6069.
48. Barber TD, Vogelstein B, Kinzler KW, et al.: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883.
49. Samuels Y, Wang Z, Bardelli A, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
50. Rajagopalan H, Bardelli A, Lengauer C, et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
51. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648.
52. Khambata-Ford SGC, Meropol NJ, Basik M, et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in matastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
53. Helena L, Issa JD, Dimitra K, et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet oncol 2008; 9: 962-972.
54. Zlobec I, Bihl MP, Schwarb H, et al.: Clinico-pathological and protein characterization of BRAF and K-RAS mutated colorectal cancer and implications for prognosis. Int J Cancer 2009; 11.
55. Sato T, Kokuba Y, Koizumi W, et al.: Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1442-1447.
56. Sato T, Kokuba Y, Koizumi W, et al.: Irinotecan and S-1 neoadjuvant chemoradiation therapy in patients with advanced rectal cancer. Hepatogastroenterology 2007; 54: 1391-1393.
57. Winder T, Mundlein A, Rhomberg S, et al.: Different type of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 2009; 21: 1283-1287.